<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309437</url>
  </required_header>
  <id_info>
    <org_study_id>PAIN-1</org_study_id>
    <nct_id>NCT02309437</nct_id>
  </id_info>
  <brief_title>Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients</brief_title>
  <official_title>Influences on the Nutrition Statuses and Clinical Outcomes of Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a superiority research, to evaluate the nutrition status, quality of
      life, influence on clinical outcome, and the adverse effects of the early use of OxyContin on
      the pain induced by radiation oral mucositis in nasopharyngeal carcinoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is a prospective, randomizing, case-controlled, multi-center clinical
      trial. 174 firstly diagnosed nasopharyngeal carcinoma patients who need radical radiation
      therapy will be randomly divided into either early intervention or common intervention group.
      OxyContin will be used to control the pain caused by radiation oral mucositis when the pain
      level is mild or moderate, respectively. Nutrition status, quality of life (QOL), and
      clinical outcomes are to be observed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS)</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizziness</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea/vomiting</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somnolence</measure>
    <time_frame>Participants will be followed for the duration of radiotherapy, an expected average of 7 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Nutrition Disorders</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Early intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Common intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Use oxycodone to treat patients with mild pain caused by radiation mucositis.</description>
    <arm_group_label>Early intervention</arm_group_label>
    <other_name>OxyContin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.</description>
    <arm_group_label>Common intervention</arm_group_label>
    <other_name>OxyContin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological confirmed nasopharyngeal carcinoma;

          2. Without historic chronic pain, no depend on analgesic drugs, no historic opioids
             intake;

          3. Plan to receive radical radiation therapy, newly to radiation for head and neck;

          4. Aged older or equal to 18 years old;

          5. Could understand and cooperate to accomplish pain evaluation and observation scales;

          6. Sufficient liver and kidney function: alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) less than 2.5* upper limit of normal (ULN), serum creatinine
             less than 1.5*ULN;

          7. Without other serious critical organ dysfunction, such as heart or lung dysfunction;

          8. Performance status (PS) score less than 2;

          9. Voluntary to participate and sign informed consent document;

         10. Obey the rules of trail; could be followed-up on time.

        Exclusion Criteria:

          1. Excluded by inclusion criteria;

          2. Known or suspected allergy to nonsteroidal anti-inflammatory drug (NSAID) or opioid
             medicine;

          3. Unable to complete the follow-up;

          4. Severe uncontrollable infections of medical disorders;

          5. Major organ including heart, lung, kidney, or liver dysfunction;

          6. With pathophysiological factors affecting drug absorption, distribution, metabolism or
             excretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-ping Chen, M. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Center of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bin Qi, M. D.</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Center of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin Qi, M. D.</last_name>
    <phone>+862066673666</phone>
    <phone_ext>1090</phone_ext>
    <email>qibin020@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong-ping Chen, M. D.</last_name>
    <phone>+862066673604</phone>
    <email>chen_dpgz@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center Of Guangzhou Medical University</name>
      <address>
        <city>Guang Zhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Qi, M. D.</last_name>
      <phone>+862066673604</phone>
      <email>qibin020@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Dong-ping Chen, M. D.</last_name>
      <phone>+862066673666</phone>
      <phone_ext>1090</phone_ext>
      <email>chen_dpgz@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guangzhou Panyu Center Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jia-yin Hu, M. D.</last_name>
      <phone>+862034858888</phone>
      <email>qibin020@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hai-qiang Mai, M. D.</last_name>
      <phone>+862087343088</phone>
      <email>maihq@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii139-54.</citation>
    <PMID>22997447</PMID>
  </reference>
  <reference>
    <citation>Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012 Feb;13(2):e58-68. doi: 10.1016/S1470-2045(12)70040-2. Review.</citation>
    <PMID>22300860</PMID>
  </reference>
  <reference>
    <citation>Takase H, Sakata T, Yamano T, Sueta T, Nomoto S, Nakagawa T. Advantage of early induction of opioid to control pain induced by irradiation in head and neck cancer patients. Auris Nasus Larynx. 2011 Aug;38(4):495-500. doi: 10.1016/j.anl.2010.12.012. Epub 2011 Jan 31.</citation>
    <PMID>21277720</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Pain</keyword>
  <keyword>Oxycodone</keyword>
  <keyword>Opioids</keyword>
  <keyword>Oral Mucositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

